Stomatitis News and Research

RSS

Investigational vaccine protects macaques against four types of hemorrhagic fever viruses

Scientists funded by the National Institutes of Health have developed an investigational vaccine that protected cynomolgus macaques against four types of hemorrhagic fever viruses endemic to overlapping regions in Africa.

8 Nov 2019

Ebola virus vaccine still effective against the infection even in low concentrations

The Ebola virus (EBOV), variant Makona, was the causative agent of the 2014-2016 West African epidemic that took over 11,000 lives and infected nearly 30,000 people. But with the combination of globally-supported containment efforts, health experts were able to track the spread of the outbreak, as well as use precautionary and quarantine procedures.

21 Oct 2019

Highly diluted candidate Ebola vaccine remains fully protective against disease in macaques

A single dose of a highly diluted VSV-Ebola virus vaccine--approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC)--remains fully protective against disease in experimentally infected monkeys, according to National Institutes of Health scientists.

18 Oct 2019

Scientists show how the immune system reacts to Ebola vaccine

Following the dramatic Ebola epidemic in West Africa from 2013 to 2016, viral infections have spread in the Democratic Republic of Congo since 2018. Since then, more than 2,100 deaths have been reported and the number of victims and new infections increases daily.

10 Oct 2019

CRISPR RNA-cutting enzyme programmed to destroy viruses in human cells

Many of the world's most common or deadly human pathogens are RNA-based viruses -- Ebola, Zika and flu, for example -- and most have no FDA-approved treatments.

10 Oct 2019

Scientists develop universal FACS-based approach to heterogenous cell sorting, propelling organoid research

Researchers have developed three novel FACS protocols that can be used to isolate neural progenitors, astrocytes, and neurons from infected cerebral organoids.

19 Jun 2019

Starving the fungus could help fight drug-resistant fungal infections

How do you fight a fungal infection that is becoming increasingly resistant to medicine? By starving it, found a team of University at Buffalo and Temple University researchers.

26 May 2019

FDA extends indication of metastatic breast cancer treatment to include male patients

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

5 Apr 2019

Viruses behave altruistically to avoid the immune system, study shows

Pilar Domingo, Ernesto Segredo, María Durán and Rafael Sanjuán, from the Institute of Integrated Systems Biology, a mixed center of the University of Valencia and the Spanish National Research Council, have shown that viruses behave altruistically to avoid the immune system.

11 Mar 2019

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Unique experimental vaccine against Zika virus proves powerful in mice

A uniquely designed experimental vaccine against Zika virus has proven powerful in mice, new research has found.

6 Aug 2018

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

2 Jul 2018

Unique patch could revolutionize treatment of painful recurring ulcers

A plaster which sticks to the inside of your mouth is revolutionising the treatment of painful recurring ulcers.

25 Jun 2018

UB researchers build 3D-printed, drug-filled dentures to fight against infections

Nearly two-thirds of the U.S. denture-wearing population suffer frequent fungal infections that cause inflammation, redness and swelling in the mouth.

26 Apr 2018

FDA grants approval for first drug to treat inherited breast cancer

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.

15 Jan 2018

Stomatitis News and Research

Investigational vaccine protects macaques against four types of hemorrhagic fever viruses

Ebola virus vaccine still effective against the infection even in low concentrations

Highly diluted candidate Ebola vaccine remains fully protective against disease in macaques

Scientists show how the immune system reacts to Ebola vaccine

CRISPR RNA-cutting enzyme programmed to destroy viruses in human cells

Scientists develop universal FACS-based approach to heterogenous cell sorting, propelling organoid research

Starving the fungus could help fight drug-resistant fungal infections

FDA extends indication of metastatic breast cancer treatment to include male patients

Viruses behave altruistically to avoid the immune system, study shows

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Unique experimental vaccine against Zika virus proves powerful in mice

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

Unique patch could revolutionize treatment of painful recurring ulcers

UB researchers build 3D-printed, drug-filled dentures to fight against infections

FDA grants approval for first drug to treat inherited breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News